KalVista Pharmaceuticals logo

KalVista Pharmaceuticals

KALV | NASDAQ
Chart Builder DCF Calculator
$27.00
$0.00 (0.00%)
At close: Jun 10, 2026, 4:00 PM ET
+0.00%

No price chart data available for 1D timeframe.

Rating

Updated: Sep 30, 2026
40.1
+11.4 pts
Fundamentals Average
Market Sentiment Neutral
Moat None

Key Statistics

Market Data

Market Cap $1.44B
1D Range
26.98 27.00
52W Range
9.83 27.00

Valuation (TTM)

PE -8.36
PB -530.25
EV/EBITDA -12.13

Valuation (NTM)

Forward PE 107.23
Forward PEG 0.15
Price Target $27.00
Loading financial charts...

Profile

KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with si...

Sector Healthcare
Industry Biotechnology
Employees 275
IPO Date Apr 9, 2015
Fiscal Year May - April

Latest News

Chiesi Group Completes Acquisition of KalVista Pharmaceuticals

5 months ago · businesswire.com

Chiesi Group Completes Acquisition of KalVista Pharmaceuticals
KalVista Pharmaceuticals (KALV) Upgraded to Buy: What Does It Mean for the Stock?

6 months ago · zacks.com

KalVista Pharmaceuticals (KALV) Upgraded to Buy: What Does It Mean for the Stock?
KalVista Pharmaceuticals Presents New Data Highlighting the Burden of Injectable On-Demand Treatment in Young Children with Hereditary Angioedema

6 months ago · businesswire.com

KalVista Pharmaceuticals Presents New Data Highlighting the Burden of Injectable On-Demand Treatment in Young Children with Hereditary Angioedema
KalVista Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference

7 months ago · businesswire.com

KalVista Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference
KalVista Pharmaceuticals: Ekterly's Launch Momentum Keeps The Bull Case Alive

7 months ago · seekingalpha.com

KalVista Pharmaceuticals: Ekterly's Launch Momentum Keeps The Bull Case Alive

Analyst Summary

# of Analysts
4
Consensus
Hold
Price Target
$27.00
Upside
0.00%
Buy (2)
Hold (2)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.